Weiss Multi-Strategy Advisers’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,897	Closed	-$633K	–	798
2023 Q1	$633K	Buy	5,897 +3,897	+195%	+$449K	0.01%	538
2022 Q4	$220K	Buy	+2,000	New	+$130K	0.01%	545
2022 Q3	–	Sell	-79,757	Closed	-$2.25M	–	795
2022 Q2	$2.25M	Buy	+79,757	New	+$2.31M	0.07%	365

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Weiss Multi-Strategy Advisers's RXDX Position: Q2 2023 in Review

Weiss Multi-Strategy Advisers sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 5,897 shares — an estimated $633K sold.

Weiss Multi-Strategy Advisers first reported a position in RXDX in Q2 2022 and held it in 3 quarters. The position peaked at $2.25M in Q2 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Weiss Multi-Strategy Advisers reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 5,897 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $633K.
Weiss Multi-Strategy Advisers first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
Weiss Multi-Strategy Advisers's Prometheus Biosciences, Inc. Common Stock position peaked at $2.25M in Q2 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.